Home＞BUSINESS
Sumitomo Dainippon Begins Japan PIII for Poxel’s Diabetes Med(Dec.28.2017)
Sumitomo Dainippon Pharma and France’s Poxel have launched a PIII clinical trial program in Japan for imeglimin, an investigational type 2 diabetes drug developed by the Merck Serono spinoff, with its filing eyed for 2020, the two companies said on December 27 ...
(LOG IN FOR FULL STORY)
-
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected Apr.20
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers Apr.20
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
